相关实验视频
Updated: Jul 29, 2025

11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
22.5K
帕金森病的设备辅助疗法-来自德国Care4PD研究的结果
Odette Fründt1, Anne-Marie Hanff2,3,4, Annika Möhl5
1Department of Neurology, Klinikum Ernst von Bergmann, Charlottenstraße 72, 14467 Potsdam, Germany.
Brain sciences
|May 27, 2023
概括
设备辅助疗法 (DATs) 在德国对帕金森病 (PD) 患者未得到充分利用,尽管许多患者出现了晚期症状. 早期识别晚期PD (aPD) 可以改善治疗和长期护理的结果.
科学领域:
- 神经学 神经学
- 运动障碍 运动障碍
- 帕金森病研究 帕金森病研究
背景情况:
- 设备辅助疗法 (DAT) 对于管理晚期帕金森病 (PD) 至关重要.
- 目前关于德国DAT使用情况的数据有限.
- 了解晚期PD (aPD) 症状的患病率对于优化患者护理至关重要.
研究的目的:
- 在德国帕金森病 (PD) 患者群体中评估DAT的应用频率和类型.
- 确定患有高级PD (aPD) 症状的患者的比例,以及他们对DAT的需求.
- 为了比较患有和没有疑似aPD的患者之间的症状负担和长期护理需求.
主要方法:
- 来自Care4PD患者调查的数据分析,其中包括1269名帕金森病患者 (PwP).
- 对DAT使用的评估,主要是深度大脑刺激 (DBS).
- 评估aPD标准,症状频率和长期护理 (LTC) 的需要.
主要成果:
- 只有12%的帕金森病 (PD) 患者使用设备辅助疗法 (DAT),主要是深度大脑刺激 (DBS).
- 超过50%的非DAT患者符合高级PD (aPD) 的标准.
- 最令人烦的是性/刚性和自主性问题;晚期PD (aPD) 患者报告了更多的运动波动和跌倒.
结论:
- 德国设备辅助疗法 (DAT) 的采用率很低,尽管有大量帕金森病 (PD) 患者表现出晚期 (aPD) 症状.
- DATs可以缓解许多烦人的症状,并可能减少对长期护理 (LTC) 的需求.
- 推实施精确的,早期识别高级PD (aPD) 症状,用于DAT选择和患者教育.
相关概念视频
Parkinson's Disease: Treatment
308
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
308
Parkinson's Disease: Overview
614
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
614
Alzheimer's Disease: Treatment
226
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
226
Drug Therapy
74
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
74

